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Background: Although diabetes mellitus is an important risk factor of coronary artery disease (CAD), routine
screening for CAD is not recommended for asymptomatic diabetic patients. We assessed the impact of chest pain
on CAD risk according to the presence or absence of diabetes mellitus.
Methods: We investigated the future CAD event rate in subjects with and without chest pain according to the
presence or absence of diabetes in a prospective large-scale community-based study in Korea.
Results: Among 8,574 subjects (4,032 men and 4,542 women) without a history of CAD, 0.8% and 2.2% of non-
diabetic and diabetic subjects, respectively, reported newly developed CAD events during 4 years of follow-up.
Although the presence of chest pain at baseline was also significantly associated with an increased risk of CAD of
more than 2-fold in both non-diabetic and diabetic subjects (P < 0.01), the risk of future CVD event in asymptomatic
diabetic patients was not significantly different from that in non-diabetic subjects with chest pain (hazard ratio,
0.907; 95% confidence interval, 0.412 – 1.998).
Conclusions: The CAD event rate of asymptomatic subjects with diabetes was comparable to that of non-diabetic
subjects reporting chest pain. Considering the high risk of CAD in asymptomatic diabetic patients, more clinical
trials aimed at formulating strategies to screen asymptomatic diabetic subjects should be carried out.
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A large population-based study has suggested that
diabetes mellitus is a coronary artery disease (CAD)
equivalent [1]. Therefore, it might be very valuable to be
able to predict which patients with diabetes will have
silent ischemia. However, recent studies have concluded
that a conventional risk factor-based approach cannot
identify high-risk patients in screening tests [2,3], and
that there is no clinical benefit of routine screening of
asymptomatic patients with diabetes [2,4]. Furthermore,
since recent randomized controlled studies have shown* Correspondence: mkmoon@snu.ac.kr
1Department of Internal Medicine, Seoul National University College of
Medicine, 39 Boramae Road, Seoul, Dongjak-Gu 156-707, South Korea
2Department of Internal Medicine, Boramae Medical Center, Seoul,
South Korea
© 2013 Koo et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthat cardiac reperfusion therapy does not produce better
clinical outcomes than medical therapy for stable CAD
[5,6], these observations have raised the question of
whether or not asymptomatic patients with diabetes
should be screened for CAD and experts recommends
that candidates for cardiac testing should be limited to
those with (i) typical or atypical cardiac symptoms and
(ii) an abnormal resting electrocardiogram (ECG) [7].
However, the prevalence of silent myocardial ischemia
in asymptomatic diabetic patients with no cardiac history
and with a normal 12-lead ECG at rest has been reported
to be high (~35%) [8] and such asymptomatic diabetic
patients suffer more future cardiac events than sympto-
matic patients do despite similar coronary atherosclerosis
severity [9]. In the Detection of Ischemia in Asymptomatic
Diabetics (DIAD) study, a large randomized clinical trial. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with diabetes, only 15% of subjects classified as
having moderate or large perfusion defects underwent
coronary angiography within 120 days after screening [4],
which might account for the lack of a significant differ-
ence between the screened and unscreened groups in that
study.
Therefore, we investigated the future CAD event rate in
diabetic patients with and without chest pain in a pro-
spective community-based cohort study performed in the
Korean population. In addition, we assessed the impact of
chest pain on CAD risk according to the presence or
absence of diabetes mellitus.
Methods
Ansung–Ansan cohort design
The Ansung and Ansan cohorts represent rural and
urban areas of Korea, respectively. The design and base-
line characteristics of these cohorts have been described
elsewhere [10,11]. Briefly, the Ansung–Ansan cohort
was established for a prospective large-scale community-
based epidemiologic study to investigate chronic diseases
in Korea. The eligibility criteria were age 40–69 years
old and residence within the borders of the survey areas
for at least 6 months before testing. In Ansung, 5,018 of
7,192 eligible individuals were surveyed (70% response
rate) using a cluster sampling method stratified by age,
sex, and residential district. Ansan is a representative
urban community that had a population of 554,998 in
2000 [12]; 5,020 of 15,580 eligible subjects (32.4%) were
recruited for the survey through a random sampling
method using the local telephone directory. The baseline
survey was performed from 2000–2001, and biennial
follow-up surveys have been performed since then.
Throughout the study, data were collected by the same
trained researchers and instruments. Anthropometric
parameters and blood pressure were measured by stand-
ard methods. The fasting plasma concentrations of
glucose, HbA1c, total cholesterol, triglycerides and HDL
cholesterol were measured in a central laboratory as
described previously [10,11].
Participants completed questionnaires in face-to-face
interviews about demographics and previous medical
history, including myocardial infarction, heart failure,
smoking, medication such as anti-hypertensive drugs or
anti-diabetic drugs, and subjective symptoms such as
chest pain and dyspnea.
This study was carried out in accordance with the Dec-
laration of Helsinki (http://www.wma.net/en/30publica-
tions/10policies/b3/index.html). Informed written consent
was obtained from all participants. The study protocol
was approved by the ethics committee of the Korean
Center for Disease Control and the Ajou University
School of Medicine Institutional Review Board.Definitions
Cases of diabetes mellitus were defined as subjects who
used anti-diabetic medication including insulin at the
time of the survey, had HbA1c ≥ 6.5% or 8-hour fasting
plasma glucose ≥ 7.0 mmol/L. Hypertension was defined
as systolic blood pressure ≥ 140 mmHg, diastolic blood
pressure ≥ 90 mmHg, or taking antihypertensive medi-
cations. Cases with systolic blood pressure ≥ 140 mmHg
or diastolic blood pressure ≥ 90 mmHg were classified as
“uncontrolled hypertension.” Dyslipidemia was defined as
triglycerides ≥ 1.7 mmol/L after at least 12 hours of
fasting, LDL cholesterol ≥ 4.1 mmol/L according to NCEP
criteria [13], or taking any lipid-lowering medications.
ECG abnormalities suggesting myocardial ischemia at
baseline included ST depression ≥ 1.0 mm, T wave inver-
sion ≥ 5.0 mm, ST elevation ≥ 1.0 mm or Q wave at any
lead. The definition of a CAD event for next 4 years of
follow-up was based on the questionnaire administered in
biennial follow-up surveys. Subject with CAD events was
defined as subject who answered that they took medica-
tion or underwent reperfusion therapy or bypass surgery
for any CAD including myocardial infarction. A family
history of CAD was defined as when a subject had at least
one first-degree relative suffering from CAD. Information
about the perception of chest pain according to activity
intensity in daily life at baseline was also obtained from
the questionnaire. The questionnaire on chest pain com-
prised questions about the presence of any type of chest
pain in daily life, during mild-intensity activity such as
walking, and moderate-intensity activity such as climbing
stairs. The characteristics of chest pain at each activity
level were further categorized as “heaviness,” “tightness or
squeezing,” “burning,” “stabbing,” or “lancinating”. Typical
angina chest pain of CAD was defined by its characteris-
tics, described as heaviness, tightness, or squeezing.
Statistical analysis
All data were analyzed by SPSS (SPSS Inc., Chicago, IL,
USA). The results are presented as means ± SD. We
logarithmically transformed waist circumference, trigly-
ceride concentration, HDL cholesterol concentration,
BMI, and urine albumin-to-creatinine ratio for analysis.
To determine the significance of differences between
baseline clinical characteristics in the development of
CAD events during the follow-up period, linear regres-
sion and logistic regression analyses adjusted for age
were used. In the case of categorical variable, general
linear model was used. Cox regression analysis with
dummy variables (to contrast the different categories)
was used to analyze the hazard ratio (HR) of diabetes
and chest pain at baseline for future CAD events
adjusted for age, sex and BMI; non-diabetic subjects
without chest pain were used as a reference risk group.
Hazard function from Cox regression analysis adjusting
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event according to chest pain and diabetes. The level of
significance was set at P < 0.05.
Results
Baseline characteristics
Of the 10,038 subjects in the Ansung–Ansan cohort, we
included 8,574 subjects (4,032 men and 4,542 women)Table 1 Baseline characteristics of subjects with or without co
Subjects without diabetes
No CAD at follow-up CAD at fo
N (% Men) 7314 (46.5) 57 (40
Ansung (% Men) 3289 (43.7) 36 (36
Ansan (% Men) 4025 (48.7) 21 (47
Age (years) 51 ± 9 56 ±
BMI (kg/m2) 24.4 ± 3.1 25.7 ±
Waist circumference (cm) Men 83.2 ± 7.5 86.5 ±
Women 80.6 ± 9.5 87.4 ±
Systolic blood pressure (mmHg) 116 ± 18 121 ±
Diastolic blood pressure (mmHg) 74 ± 12 76 ±
HbA1C (%) 5.5 ± 0.3 5.6 ±
Fasting glucose (mmol/L) 4.7 ± 0.5 4.7 ±
Total cholesterol (mmol/L) 4.93 ± 0.90 5.21 ±
HDL cholesterol (mmol/L) Men 1.16 ± 0.27 1.25 ±
Women 1.24 ± 0.28 1.22 ±
Triglyceride (mmol/L) 1.68 ± 1.06 1.95 ±
Serum creatinine (μmol/L) 74 ± 18 72 ±
Urine microalbuminuria(mg/g Cr) 97 ± 244 79 ±
Normal (%) 17.2 8.7
Microalbuminuria (%) 79.3 91.3
Proteinuria (%) 3.0 0.0
Smoker
Non-smoker (%) 59.9 57.9
Ex-smoker (%) 15.1 17.5
Smoker (%) 25.0 24.6
Family history of CAD, N (%) 22 (0.3%) 0 (0
Hypertension, N (%) 1355 (18.5) 19 (33
Antihypertensive drug, N (%) 591 (8.1) 14 (24
Hypertension, uncontrolled, N (%)b 990 (13.5) 9 (15
Dyslipidemia, N (%) 3051 (41.7) 34 (59
Cholesterol-lowering drug, N (%) 20 (0.3) 0
Triglyceride ≥ 1.7 mmol/L, N (%) 2627 (35.9) 31 (54
LDL cholesterol < 4.1 mmol/L, N (%) 6562 (89.7) 52 (91
LDL cholesterol < 3.3 mmol/L, N (%) 4860 (66.5) 38 (66
LDL cholesterol < 2.6 mmol/L, N (%) 2212 (30.2) 17 (29
HbA1c < 7%, N (%) - -
Living in urban area (Ansan) (%) 51.4% 33.3%
Abbreviations: CAD, coronary artery disease.
aAge-adjusted P value; bCases with systolic blood pressure ≥ 140 mmHg or diastolic
CAD = 2.829 [1.501- 5.333]; dOR = 1.928 [1.132 – 3.285]; eOR = 2.014 [1.192 – 3.404].who had no history of ischemic heart disease and no
ECG abnormality suggesting myocardial ischemia the
present study. Among them, 1,203 (14%) had diabetes
mellitus at baseline. During a follow-up period of 4 years,
0.8% and 2.2% of non-diabetic and diabetic subjects,
respectively, reported experiencing a newly developed
CAD event (Table 1). Among 84 subjects with CAD
events during follow-up period, 16 (7 in non-diabeticronary artery disease events over 4 years of follow-up
mellitus Subjects with diabetes mellitus
llow-up Pa No CAD at follow-up CAD at follow-up Pa
.4) 0.415 1176 (50.9) 27 (48.1) 0.994
.1) 595 (43.9) 18 (55.6)
.6) 581 (58.0) 9 (33.3)
9 <0.001 56 ± 9 59 ± 9 0.050
2.9 0.001 25.6 ± 3.3 25.5 ± 3.9 0.988
6.7 0.032 86.2 ± 8.7 88.5 ± 8.8 0.262
7.5 0.001 87.1 ± 8.6 86.6 ± 8.8 0.699
15 0.249 124 ± 19 126 ± 17 0.986
9 0.805 77 ± 11 76 ± 10 0.463
0.4 0.758 7.4 ± 1.6 7.1 ± 1.5 0.513
0.4 0.700 6.9 ± 2.6 6.7 ± 2.5 0.986
0.99 0.031 5.21 ± 1.07 5.01 ± 1.10 0.402
0.38 0.327 1.11 ± 0.26 1.15 ± 0.29 0.630
0.31 0.865 1.14 ± 0.27 1.17 ± 0.23 0.600
0.99 0.032 2.31 ± 1.52 2.07 ± 0.96 0.634
14 0.506 76 ± 37 80 ± 28 0.551
60 0.665 180 ± 487 182 ± 191 0.623
10.6 0.0
0.424 79.4 80.0 0.475
10.0 20.0
56.2 53.3
0.591 16.8 16.7 0.631
27.0 30.0
) 0.998 2 (0.2) 0 (0) 1.000
.3) 0.074 425 (36.1) 14 (51.9) 0.237
.6) 0.001c 260 (22.1) 11 (40.7) 0.090
.8) 0.393 274 (23.3) 6 (22.2) 0.237
.6) 0.016d 786 (66.7) 18 (66.7) 0.959
0.998 15 (1.3) 0 0.998
.4) 0.009e 721 (61.5) 17 (63.0) 0.813
.2) 0.672 959 (81.8) 22 (81.5) 0.887
.7) 0.870 672 (57.3) 18 (66.7) 0.379
.8) 0.967 306 (26.1) 11 (40.7) 0.116
- 609 (51.8) 16 (59.3) 0.423
0.150 46.5% 30.0% 0.622
blood pressure ≥ 90 mmHg irrespective of medication; cOdds ratio (OR) for
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undergone reperfusion therapy in that period. The
presence of diabetes at baseline independently increased
the risk of future CAD risk (age-, sex-, and BMI-
adjusted odds ratio [OR] = 2.083 [95% confidence interval,
1.290 – 3.365], P = 0.003). The baseline characteristics
according to development of CAD events during the
follow-up period are shown in Table 1. Among non-
diabetic subjects, those who developed CAD were signifi-
cantly older (P < 0.001), had higher BMI (P = 0.001) and
waist circumference (WC) (P = 0.032 in men and 0.001 in
women), and had hypertriglyceridemia more frequently at
baseline (P = 0.009). However, in diabetic subjects, there
were no significant differences between subjects with and
without CAD with respect to baseline characteristics,
except age (P = 0.050). The proportions of all diabetes
patients who attained the clinical goals were as follows:
52.0% for HbA1c < 7%, 26.4% for LDL < 2.6 mmol/L, and
76.7% for blood pressure < 140/90 mmHg; none of these
parameters differed significantly between those with and
without CAD events (Table 1). Age was only a significant
risk factor of future CAD events in both men and women
in the case of diabetes (data not shown).
CAD event rate according to the presence or absence of
chest pain
At baseline, 22.8% and 19.6% of non-diabetic and dia-
betic subjects, respectively, reported having any type of
chest pain in daily life. Approximately 40% of subjects
with CAD events previously reported chest pain at base-
line irrespective of glycemic status. Among all subjects
reporting chest pain at baseline, 1.6% and 5.1% of non-
diabetic and diabetic subjects, respectively, experienced
CAD events over the next 4 years. The presence of chestTable 2 Hazard ratios (HR) of CAD events during next 4 years




(1000 person-yr) Hazard ratios
a
Chest pain, total (%)
Absence 5624 1.0 2.879
Presence 1674 2.7 (1.536 – 5.394)
Typical chest pain (%)c
Absence 6596 1.1 2.814
Presence 779 3.2 (1.370 – 5.780)
Chest pain on mild-intensity activity (%)d
Absence 7146 1.2 6.110
Presence 94 8.2 (1.861 –20.054)
Chest pain on moderate-intensity exercise (%)d
Absence 7067 1.3 2.017
Presence 192 2.7 (0.480 – 8.472)
Abbreviations: CAD, coronary artery disease.
aHazard ratio of chest pain for CAD events over the next 4 years adjusting sex and
tightness, or squeezing regardless of activity level or chest pain perception; dany chpain at baseline was significantly associated with a 2-fold
increase in future CAD risk in both non-diabetic (HR =
2.879 [1.536 – 5.394], P = 0.001) and diabetic subjects
(OR = 3.489 [1.620 – 7.512], P = 0.001) even after
adjusting for sex and age (Table 2). Exertional chest pain
during mild-degree exercise was also a significant pre-
dictive factor of CAD events in non-diabetic subjects
(Table 2). In contrast, there was no significant associ-
ation between chest pain during mild-degree exercise
and the CAD event rate in diabetic subjects.
Next, we estimated HR of CAD events according to
presence or absence of chest pain in the subjects with or
without diabetes using Cox proportional hazards model.
All study subjects were categorized into 4 groups: non-
diabetic subjects without chest pain at baseline (Group 1),
non-diabetic subjects with chest pain (Group 2), diabetic
subjects without chest pain (Group 3), and diabetic
subjects with chest pain (Group 4). Group 4 had the worst
prognosis, whereas Group 1 had the best (Figure 1).
Groups 2 and 3 had intermediate event rates as well as
similar outcomes. Table 3 presents the results of the Cox
proportional hazards model comparing the subjects in
Groups 2–4 with those in Group 1. Groups 2–4 had
significantly higher HRs than Group 1 even after adjusting
for age, sex, and other risk factor of CAD. Next, we
compared only Groups 2 and 3. The age- and sex-
adjusted HR of Group 3 was not significantly differ-
ent from that of Group 2 (HR = 0.907 [0.412 – 1.998],
P = 0.809), suggesting these groups have similar CAD
event rates.
Discussion
In our study, among 8,574 subjects without a history of
CAD, 0.8% and 2.2% of non-diabetic and diabeticaccording to the perception of chest pain at baseline






















33 23.8 (1.162 – 13.265)
age; bsex- and age- adjusted P value; cchest pain described as heaviness,
est pain associated with activity.
Figure 1 Cox proportional hazards model for the probability of
coronary artery disease (CAD) events over the 4 years. Cox
proportional hazards model for the probability of CAD events in
1,203 subjects with diabetes mellitus and 7,371 non-diabetic subjects
with and without chest pain at baseline. Gray dotted line, non-
diabetic subjects without chest pain (Group 1); gray solid line, non-
diabetic subjects with chest pain (Group 2); black dotted line,
diabetic subjects without chest pain (Group 3); black solid line,
diabetic subjects with chest pain (Group 4).
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veloped CAD events during a 4-year follow-up period;
these rates are concordant with those of the DIAD study
[4]. Our results corroborate those of earlier reports
indicating that subjects with diabetes mellitus have an
increased incidence of cardiovascular events [1,14] and
show that the presence of chest pain at baseline is
significantly associated with an increase in future CAD
risk of more than 2-fold in both non-diabetic and dia-
betic subjects.Table 3 Hazard ratios (HR) of incident CAD events over 4 yea
Model 1
HR
Non-diabetic subjects without chest pain (Group 1) 1
Non-diabetic subjects with chest pain (Group 2) 2.768
(1.485 – 5.160)
Diabetic subjects without chest pain (Group 3) 4.008
(2.079 – 7.727)
Diabetic subjects with chest pain (Group 4) 13.220
(6.543 – 26.712)
Abbreviations: CAD, coronary artery disease.
Model 1: No adjusting.
Model 2: Adjusted for age and sex.
Model 3: Adjusted for age, sex, bmi, hypertension, dyslipidemia, smoking history anInterestingly, diabetic subjects without chest pain had
a similar CAD event rate to non-diabetic subjects with
chest pain, implying that the results of clinical trials
conducted in asymptomatic non-diabetic subjects are
not applicable to asymptomatic diabetic subjects. The
well-known clinical trials which showed that revasculari-
zation was not superior to medical treatment for stable
CAD [6,15] included subjects with diabetes only 20–35%
of the study population and those results should be
carefully interpreted when applying them to diabetic
subjects.
Although the Bypass Angioplasty Revascularization
Investigation 2 Diabetes (BARI 2D) trial did not find any
difference in cardiac outcomes between revascularization
and medical treatment in the patients with diabetes, sub-
group analysis showed that the prognosis of severe CAD
lesions was better with revascularization treatment [5].
The survival of diabetic patients with silent ischemia is
known to be related to the severity of CAD [16]. Consid-
ering the fact that small proportion of subjects with
moderate or large perfusion defects underwent coronary
angiography within 120 days after screening in the DIAD
study [4], the benefit of screening might be under-
estimated in that study.
The present study also revealed that no baseline char-
acteristics, except age in diabetic subjects, were signifi-
cantly different between subjects with and without CAD,
which corroborates the results of previous studies [2,3].
In contrast, the traditional risk factors for CAD such as
age, obesity, and hypertension were significantly asso-
ciated with future CAD event rates in non-diabetic
subjects. Previous studies report that CAD risk indica-
tors other than traditional risk factors for asymptomatic
diabetic patients include autonomic neuropathy [2,17],
retinopathy [18,19], and renal complications [20,21].
However, in the present study, we only had information
on kidney function, and there was no difference in
serum creatinine level or albumin excretion ratio with
respect to CAD events in diabetic patients.rs of follow-up
Model 2 Model 3



















(5.522 – 22.881) (4.118 – 17.705)
d family history of CAD.
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with multiple risk factors might be a reason for the lack of
associations between metabolic risk factors and the devel-
opment of CAD events. In the present study, 23.2% of
diabetic patients had uncontrolled hypertension at base-
line, which is somewhat lower than the 33% reported in
the general population in the Korean National Health and
Nutrition Examination Survey in 2001 [22] and the 31%
reported in the DIAD study population [2]. Intensive
intervention with multiple drug combinations produces
sustained beneficial effects with respect to vascular com-
plications and mortality rates from any cause and car-
diovascular causes, respectively [23]. A recent US report
demonstrated that the mortality rates among both
American men and women with diabetes decreased sub-
stantially between 1997 and 2006, reducing the absolute
difference between adults with and without diabetes [24].
However, further study to determine the high-risk
population among asymptomatic diabetic patients is
warranted by the fact that diabetic patients with silent
ischemia have poor outcomes [25] and that the progno-
sis of severe CAD lesions is better with revascularization
treatment [5]. Asymptomatic diabetic patients with a
higher coronary disease burden suffer more future car-
diac events than asymptomatic patients do [26,27].
The main limitation of our study is that CAD events
were determined from questionnaires without objective
confirmatory data. The presence or absence of chest
pain was also determined from questionnaires, which
might result in underestimation. The relatively short
follow-up duration of the present study is also a limita-
tion for investigating the CAD event rate. However, the
prospective 4-year follow-up of a large community-
based cohort means our results are stronger than those
of other studies are. Furthermore, few studies have com-
pared the impacts of chest pain on future CAD in those
with and without diabetes.
Conclusions
The CAD event rate of asymptomatic subjects with dia-
betes was comparable to that of non-diabetic subjects
reporting chest pain. Considering the high risk of CAD
in asymptomatic diabetic patients and morbidity and
mortality due to CAD, more clinical trials aimed at for-
mulating strategies to screen asymptomatic diabetic sub-
jects should be carried out.
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